Physical characterization of meloxicam-β-cyclodextrin inclusion complex pellets prepared by a fluid-bed coating method

Particuology

Volumn 7, Issue 1, 2009, Pages 1-8

  Lu, Yi ^a   Zhang, Xingwang ^a   Lai, Jie ^b   Yin, Zongning ^b   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cyclodextrin; Characterization; Dissolution; Fluid bed; Inclusion complex; Meloxicam; Pellets

Indexed keywords

COMPOSITE MICROMECHANICS; DISSOLUTION; FOURIER TRANSFORMS; INFRARED SPECTROSCOPY; SPECTROMETERS; SPECTROMETRY;

CHARACTERIZATION; FLUID-BED; INCLUSION COMPLEX; MELOXICAM; PELLETS;

PELLETIZING;

EID: 59149085001     PISSN: 16742001     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.partic.2008.11.004     Document Type: Article

References (24)

1. Bouquet W., Ceelen W., Fritzinger B., Pattyn P., Peeters M., Remon J.P., et al. Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion-Formulation and stability. European Journal of Pharmaceutics and Biopharmaceutics 66 3 (2007) 391-397
2. Brewster M.E., and Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews 59 7 (2007) 645-666
3. Busch U., Schmid J., Heinzel G., Schmaus H., Baierl J., Huber C., et al. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metabolism and Disposition 26 6 (1998) 576-584
4. Corrigan O.I., and Stanley C.T. Mechanism of drug dissolution rate enhancement from beta-cyclodextrin-drug systems. Journal of Pharmacy and Pharmacology 34 10 (1982) 621-626
5. Davis M.E., and Brewster M.E. Cyclodextrin-based pharmaceutics: Past, present and future. Nature Reviews Drug Discovery 3 12 (2004) 1023-1035
6. Defazio S., and Cini R. Synthesis, X-ray structure and molecular modeling analysis of cobalt (II), nickel (II), zinc (II) and cadmium (II) complexes of the widely used anti-inflammatory drug meloxicam. Journal of the Chemical Society Dalton Transactions 9 (2002) 1888-1897
7. Figueiras A., Carvalho R.A., Ribeiro L., Torres-Labandeira J.J., and Veiga F.J.B. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics 67 2 (2007) 531-539
8. Ghorab M.M., Abdel-Salam H.M., El-Sayad M.A., and Mekhel M.M. Tablet formulation containing meloxicam and β-cyclodextrin: Mechanical characterization and bioavailability evaluation. AAPS PharmSciTech 5 4 (2004) E59
9. Hanft G., Türck D., Scheuerer S., and Sigmund R. Meloxicam oral suspension: A treatment alternative to solid meloxicam formulations. Inflammation Research 50 Suppl. 1 (2001) S35-S37
10. Jun S.W., Kim M.S., Kim J.S., Park H.J., Lee S., Woo J.S., et al. Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. European Journal of Pharmaceutics and Biopharmaceutics 66 3 (2007) 413-421
11. Latrofa A., Trapani G., Franco M., Serra M., Muggironi M., Fanizzi F.P., et al. Complexation of phenytoin with some hydrophilic cyclodextrins: Effect on aqueous solubility, dissolution rate, and anticonvulsant activity in mice. European Journal of Pharmaceutics and Biopharmaceutics 52 1 (2001) 65-73
12. Lin S.Y., and Kao Y.H. Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique. International Journal of Pharmaceutics 56 3 (1989) 249-259
13. Lipka E., and Amidon G.L. Setting bioequivalence requirements for drug development based on preclinical data: Optimizing oral drug delivery systems. Journal of Controlled Release 62 1-2 (1999) 41-49
14. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrins. 1: Drug solubilization and stabilization. Journal of Pharmaceutical Sciences 85 10 (1996) 1017-1025
15. Naidu N.B., Chowdary K.P., Murthy K.V., Satyanarayana V., Hayman A.R., and Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. Journal of Pharmaceutical and Biomedical Analysis 35 1 (2004) 75-86
16. Naidu N.B., Chowdary K.P., Murthy K.V., Becket G., and Crooks P.A. Tablet formulation studies on nimesulide and meloxicam-cyclodextrin binary systems. AAPS PharmSciTech 8 2 (2007) E36
17. Noble S., and Balfour J.A. Meloxicam. Drugs 51 3 (1996) 424-430
18. Rajendrakumar K., Madhusudan S., and Pralhad T. Cyclodextrin complexes of valdecoxib: Properties and anti-inflammatory activity in rat. European Journal of Pharmaceutics and Biopharmaceutics 60 1 (2005) 39-46
19. Stella V.J., and Rajewski R.A. Cyclodextrins: Their future in drug formulation and delivery. Pharmaceutical Research 14 5 (1997) 556-567
20. Sun N., Wei X., Wu B., Chen J., Lu Y., and Wu W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technology 182 1 (2008) 72-80
21. Tantishaiyakul V., Kaewnopparat N., and Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. International Journal of Pharmaceutics 181 2 (1999) 143-151
22. Türck D., Roth W., and Busch U. A review of the clinical pharmacokinetics of meloxicam. British Journal of Rheumatology 35 Suppl 1 (1996) S13-S16
23. Zhang X., Sun N., Wu B., Lu Y., Guan T., and Wu W. Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique. Powder Technology 182 3 (2008) 480-485
24. Zhang X., Wu D., Lai J., Lu Y., Yin Z., and Wu W. Piroxicam/2-hydroxypropyl-β-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique. Journal of Pharmaceutical Sciences 98 2 (2009) 665-675